New hope for Hard-to-Treat cancers: GAIA-102 trial targets malignant ascites
NCT ID NCT05438459
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two parts: first, to find a safe dose, and second, to see if the treatment helps people live longer compared to standard therapy. About 130 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GAIA-102 (a biological therapy) and pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could offer a new treatment option for advanced gastrointestinal cancers with malignant ascites, potentially extending survival and controlling disease.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply broadly. There are risks of side effects from the therapies, and the combination may not prove more effective than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kyushu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••